Dopamine Reduction in the Substantia Nigra of Parkinson's Disease Patients Confirmed by In Vivo Magnetic Resonance Spectroscopic Imaging

Morphological and Metabolic Changes in the Nigro-Striatal Pathway of Synthetic Proteasome Inhibitor (PSI)-Treated Rats: A MRI and MRS Study

(2013) Stefano Delli Pizzi et al.   PLoS One

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

(2012) Changho Choi et al.   NATURE MEDICINE

Elevated Pontine and Putamenal GABA Levels in Mild-Moderate Parkinson Disease Detected by 7 Tesla Proton MRS

(2012) Uzay E. Emir et al.   PLoS One

Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson’s disease

(2011) Adriane Gröger et al.   EUROPEAN RADIOLOGY

Longitudinal inter- and intra-individual human brain metabolic quantification over 3 years with proton MR spectroscopy at 3 T

(2011) Ivan I. Kirov et al.   MAGNETIC RESONANCE IN MEDICINE

Glutathione—a review on its role and significance in Parkinson’s disease

(2009) Heather L. Martin et al.   FASEB JOURNAL

Anatomy of the Substantia Nigra and Subthalamic Nucleus on MR Imaging

(2009) L.A. Massey et al.   NEUROIMAGING CLINICS OF NORTH AMERICA

Comparative test–retest reliability of metabolite values assessed with magnetic resonance spectroscopy of the brain. The LCModel versus the manufacturer software

(2009) Nicolas Fayed et al.   NEUROLOGICAL RESEARCH